Doctors In-Vivo Pharma Companies Regulation 
pharmaphorum
JANUARY 29, 2021
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Zinc fingers. billion in funding.
XTalks
OCTOBER 1, 2020
To gain insight into the motivations, steps and experiences involved in an academia to industry — or vice versa — transition, Xtalks spoke to several leading scientists and entrepreneurs in pharma and biotech who successfully transitioned from academic positions to leadership roles in industry settings. Key Moments.
Expert insights. Personalized for you.
141 
Let's personalize your content